ReviewStem cells (Dayton, Ohio)2013
Concise review: role of DEK in stem/progenitor cell biology.
Review in Stem cells (Dayton, Ohio), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- NUP214 in Acute Myeloid Leukemia.Cells · 2025Review
- DEK-nucleosome structure shows DEK modulates H3K27me3 and stem cell fate.Nature structural & molecular biology · 2025Article
- DEK, a nuclear protein, is chemotactic for hematopoietic stem/progenitor cells acting through CXCR2 and Gαi signaling.Journal of leukocyte biology · 2022Article
- Nuclear DEK preserves hematopoietic stem cells potential via NCoR1/HDAC3-Akt1/2-mTOR axis.The Journal of experimental medicine · 2021Article
- Role of the DEK oncogene in the development of squamous cell carcinoma.International journal of clinical oncology · 2020Review
- DEK Is a Potential Biomarker Associated with Malignant Phenotype in Gastric Cancer Tissues and Plasma.International journal of molecular sciences · 2019Article
- Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.The Journal of clinical investigation · 2019Article
- NUP214 in Leukemia: It's More than Transport.Cells · 2019Review
- Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis.Journal of Cancer · 2019Article
- Prognostic role of DEK in human solid tumors: a meta-analysis.Oncotarget · 2017Article
- A role for intracellular and extracellular DEK in regulating hematopoiesis.Current opinion in hematology · 2017Review
- The DEK Oncoprotein Is a Critical Component of the EKLF/KLF1 Enhancer in Erythroid Cells.Molecular and cellular biology · 2015Article
- Review
- Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.Oncotarget · 2015Article
- Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer.Journal of oncology · 2015Review
- A DEK domain-containing protein modulates chromatin structure and function in Arabidopsis.The Plant cell · 2014Article
- The PML-associated protein DEK regulates the balance of H3.3 loading on chromatin and is important for telomere integrity.Genome research · 2014Article
- Inhibiting HDAC for human hematopoietic stem cell expansion.The Journal of clinical investigation · 2014Article
- Poly(ADP-Ribosyl) Code Functions.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Understanding the factors that regulate hematopoiesis opens up the possibility of modifying these factors and their actions for clinical benefit. DEK, a non-histone nuclear phosphoprotein initially identified as a putative proto-oncogene, has recently been linked to regulate hematopoiesis. DEK has myelosuppressive activity in vitro on proliferation of human and mouse hematopoietic progenitor cells and enhancing activity on engraftment of long-term marrow repopulating mouse stem cells, has been linked in coordinate regulation with the transcription factor C/EBPα, for differentiation of myeloid cells, and apparently targets a long-term repopulating hematopoietic stem cell for leukemic transformation. This review covers the uniqueness of DEK, what is known about how it now functions as a nuclear protein and also as a secreted molecule that can act in paracrine fashion, and how it may be regulated in part by dipeptidylpeptidase 4, an enzyme known to truncate and modify a number of proteins involved in activities on hematopoietic cells. Examples are provided of possible future areas of investigation needed to better understand how DEK may be regulated and function as a regulator of hematopoiesis, information possibly translatable to other normal and diseased immature cell systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.